Silo Pharma shares surge 16.63% premarket after signing LOI with Allucent for SPC-15 Phase 1 clinical trials.

think> Okay, let's tackle this query step by step. The user wants me to act as a financial analyst explaining Silo Pharma's stock price movement in the premarket. The stock is up 16.63% in premarket trading. I need to look at the provided news events and determine which ones are relevant and caused the movement. First, I'll check the stock performance: Silo Pharma is up 16.63% premarket. The key here is to see which news events could have caused such a significant jump. Looking at the news reasons: Reason 1: Nasdaq extension to regain compliance. The company got an extra 180 days until June 2026. This is positive because it gives them more time to meet the $1 bid price requirement. The stock was trading at $0.36, so this extension is a relief, reducing the risk of delisting. This is a bullish event. Reason 2 and 3: Both are about the LOI with Allucent for Phase 1 trials of SPC-15. These are significant because moving into Phase 1 is a major milestone for a drug candidate. The collaboration with a CRO suggests progress in their pipeline, which is positive for the company's long-term value. This is another bullish point. Reason 4 and 5: These reiterate the Nasdaq extension, so similar to Reason 1. They confirm the same positive news. Reason 6: Seems to be in a different language (Polish) but likely the same as the Nasdaq extension. Since the content is cut off, I'll rely on the summary provided in Reason 4 and 5. Now, the stock is up, so we need to see which of these news events align with that movement. The Nasdaq extension is a positive because it gives the company more time and reduces the immediate threat of delisting. The LOI with Allucent is also positive as it's a step forward in their drug development, which could lead to future growth. The user's example shows that multiple relevant news events can be cited, but the example only used one. However, in this case, there are two major positive events: the Nasdaq extension and the LOI for Phase 1 trials. The stock's significant premarket gain is likely due to both, but I need to check if both are from the same time frame. The Nasdaq extension was on Dec 24, 2025, and the LOI was on Dec 30, 2025. The trading period mentioned is premarket, so if the LOI was announced on Dec 30, the premarket trading on that day would reflect that news. However, the Nasdaq extension was on Dec 24, so if the current date is after Dec 30, the premarket move could be due to the LOI. But the user didn't specify the exact date of the stock movement. Wait, the user's input says "Trading Period: premarket" but doesn't specify the exact date. However, the news events mention Dec 24 and Dec 30, 2025. Assuming the premarket trading in question is on Dec 30, then the LOI announcement would be the most recent news. However, the Nasdaq extension was on Dec 24, so if the premarket is on a later date, perhaps the LOI is the main driver. But the user hasn't provided the exact date of the stock movement. This is a bit ambiguous. However, given the information, the two major positive news events are the Nasdaq extension and the LOI with Allucent. Both are relevant and could contribute to the stock's premarket rise. However, the 16.63% jump is quite large, so it's more likely that the LOI is the primary catalyst, as regulatory extensions are often seen as temporary reprieves but not as significant as a major step in drug development. The LOI for Phase 1 trials is a more substantial positive event. Therefore, the stock's movement is likely driven by the LOI with Allucent for the Phase 1 trials. The Nasdaq extension is positive but may not explain such a large increase. However, since the user's example includes multiple relevant news, but in this case, the two are both recent, I need to check if both can be included. However, the example only used one. The user's instruction says to identify the key news likely causing the move. Given the significant increase, the LOI is the key driver. The Nasdaq extension is a relief but may not account for a 16.63% gain. Therefore, the answer should focus on the LOI with Allucent for the Phase 1 trials as the primary cause. However, I need to check the dates. If the premarket trading is on Dec 30, the LOI.